Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.

Trial Details

NCT ID

NCT07231445

Phase

PHASE1

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

ZG006
Serplulimab

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Participants with histologically or cytologically confirmed ES-SCLC.
Fully understand the study and voluntarily sign the informed consent form;
Male or female 18\~75 years of age;
Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →